1. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC)
   Pedro Barata et al, 2018, Investigational New Drugs CrossRef
2. Small-Molecule Protein Tyrosine Kinase Inhibitors for the Treatment of Metastatic Prostate Cancer
   Gary E Gallick et al, 2012, Future Medicinal Chemistry CrossRef
3. In search for geroprotectors: in silico screening and in vitro validation of signalome-level mimetics of young healthy state
   Alexander Aliper et al, 2016, Aging CrossRef